At cCARE, we believe in the power of cancer research and the hope it gives to millions of patients worldwide. In fact, we have more patients involved with national and pharmaceutical clinical trials than any other cancer treatment center in the central valley. Our participation in this research has improved cancer care for people in our geographic region and around the world. These clinical trials cover a broad spectrum of diagnosis and include cancer, non-cancer, prevention and symptom management studies.

cCARE is dedicated to cancer research with ongoing clinical trials with specific departments focused solely on these studies. By participating in these clinical trials, cCARE has privileged access to treatment options that would not otherwise be available. Implementing the proper techniques with world-renowned research institutions is another example of cCARE committment to treatment. These leading edge therapies significantly increase treatment options for our patients, which aide in the plight against cancer. These trials not only have a direct benefit on our patients’ health, but they deliver positive results which can be shared and utilized in clinics worldwide. We take pride in our ongoing clinical trials with various research groups such as the prestigious Mayo Clinic. It is our quest to continually strive to reduce the number of cancer patients, deliver the most advanced forms of procedures and promote novel approaches to ongoing treatment.

cCARE are members of the following research groups:

• NCCTG (North Central Cancer Treatment Group affiliate through The Mayo Clinic)
http://ncctg.mayo.edu/

cCARE are currently involved in clinical trials concerning breast cancer, colorectal cancer, pancreatic cancer, lung cancer and ovarian cancer.

cCARE Trials Open to Accrual

Bone Marrow
CBIO-BB005.V.1 Biospecimen Collection and Use for Future Scientific Research of Bone Marrow Biopsies from ALL, AML, CLL, MM and CML patients.

Breast
ML 28257: An observational cohort study of treatment patterns and outcomes in patients with Her2 positive (HER2+) Metastatic Breast Cancer
MM-121-04-01-04: Phase 1 Pharmacologic & Pharmacodynamic study of MM-121 in combination with Paclitaxel in patients with advanced breast cancers
NBRST: Prospective neo-adjuvant REGISTRY trial linking MammaPrint, Subtyping and treatment response: Neoadjuvant Breast Registry - Symphony Trial
CBKM120F2302: A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment
GO28509: A Phase II, Randomized Study of Paclitaxel with GDC-0941 versus Paclitaxel with Placebo in Patients with Locally Recurrent or Metastatic Breast Cancer
SPI-GCF-12-201: Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy with the Docetaxel + Cyclophophamide (TC) Regimen

Chronic Lymphocytic Leukemia
GS-US-312-0119: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Colorectal
I4T-MC-JVBB: A randomized, double-blind, study of Irinotecan, Folinic Acid, and 5-Fluorouracil (Folfiri) plus Ramucirumab or Placebo in patients with metastatic colorectal carcinoma progressive during or following first-line combination therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine.
ML 25710 (MAVERICC): A Randomized Phase 2 Study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI With Biomarker Stratification In Patients With Previously Untreated Metastatic Colorectal Cancer
TPU-TAS-102-301: Randomized, double-blind, phase 3 study of TAS-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer refractory to standard chemotherapies

Lung
MO22097: An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy

Multiple Myeloma
20090482: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
Onyx: 2012-005: A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan and Prednisone versus Bortezomib, Melphalan and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Myelodysplastic Syndrome.
AZA-MDS-003: A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes

Prostate.
RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy ( SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
SPI-153-10-1: An International, Multicenter, Open Label, Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix versus Goserelin Depot (Zoladex®) in Men with Prostate Cancer